Renopulmonary Syndromes: A Comprehensive Approach

 

Renopulmonary Syndromes: A Comprehensive Approach to Diagnosis, Radiology and Management

Dr Neeraj Manikath,Claude.ai

Abstract

Renopulmonary syndromes encompass a group of disorders characterized by concurrent renal and pulmonary manifestations, often presenting as diagnostic and therapeutic challenges in critical care settings. This article provides a systematic approach to the diagnosis, radiological evaluation, and management of these complex conditions, focusing on the most common entities including anti-glomerular basement membrane disease (Goodpasture's syndrome), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA), and systemic lupus erythematosus (SLE). Understanding the pathophysiological mechanisms, diagnostic approaches, and therapeutic interventions is crucial for critical care specialists managing these potentially life-threatening conditions.

1. Introduction

Renopulmonary syndromes represent a heterogeneous group of disorders characterized by the concurrent involvement of the kidneys and lungs. These conditions typically manifest with varying combinations of pulmonary hemorrhage and glomerulonephritis, presenting significant diagnostic and therapeutic challenges in critical care settings. The early recognition and prompt management of these syndromes are essential for improving patient outcomes and preventing irreversible organ damage.

The primary pathophysiological mechanisms underlying renopulmonary syndromes involve immune-mediated injury, particularly autoantibody-mediated damage to both pulmonary and renal tissues. The most commonly recognized entities include:

1. Anti-glomerular basement membrane (anti-GBM) disease (Goodpasture's syndrome)
2. ANCA-associated vasculitides:
   • Granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis)
   • Microscopic polyangiitis (MPA)
   • Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome)
3. Systemic lupus erythematosus (SLE)
4. Immunoglobulin A (IgA) vasculitis (Henoch-Schönlein purpura)
5. Cryoglobulinemic vasculitis

This article provides a comprehensive review of the approach to diagnosis, radiological evaluation, and management strategies for renopulmonary syndromes, with a focus on evidence-based practices relevant to critical care medicine.

2. Pathophysiology of Renopulmonary Syndromes

The pathogenesis of renopulmonary syndromes primarily involves autoimmune mechanisms targeting structures common to both the lungs and kidneys. Understanding these mechanisms is essential for diagnostic and therapeutic approaches.

2.1 Anti-GBM Disease (Goodpasture's Syndrome)

In anti-GBM disease, autoantibodies target the α3 chain of type IV collagen, a component of basement membranes in both glomerular and alveolar structures. The binding of these antibodies activates complement and recruits inflammatory cells, leading to tissue damage. The characteristic linear deposition of IgG along the basement membranes is the hallmark of this condition.

2.2 ANCA-Associated Vasculitides

ANCA-associated vasculitides involve antibodies against neutrophil cytoplasmic components:

• GPA: Characterized by PR3-ANCA (c-ANCA) positivity in approximately 80-90% of cases, with granulomatous inflammation affecting the upper and lower respiratory tracts and necrotizing glomerulonephritis.

• MPA: Associated with MPO-ANCA (p-ANCA) in 50-80% of patients, featuring necrotizing vasculitis without granulomatous formation.

• EGPA: Characterized by eosinophilic infiltration, extravascular granulomas, and necrotizing vasculitis, with MPO-ANCA positivity in about 40% of cases.

2.3 Systemic Lupus Erythematosus

Lupus nephritis and pulmonary manifestations in SLE result from immune complex deposition and complement activation. The characteristic "full house" immunofluorescence pattern in renal biopsies reflects deposits of IgG, IgA, IgM, C3, and C1q.

3. Clinical Presentation

The clinical manifestations of renopulmonary syndromes vary depending on the underlying etiology and the extent of organ involvement.

3.1 Pulmonary Manifestations

Diffuse alveolar hemorrhage (DAH) is a life-threatening manifestation common to several renopulmonary syndromes, presenting with:

• Hemoptysis (may be absent in up to 33% of cases)
• Dyspnea
• Hypoxemia
• Diffuse alveolar infiltrates on imaging
• Anemia
• Increased DLCO (diffusing capacity for carbon monoxide)

Other pulmonary manifestations include:

• Nodules and cavitations (particularly in GPA)
• Interstitial lung disease (more common in SLE)
• Asthma and eosinophilic pneumonia (characteristic of EGPA)
• Pleural effusions (more common in SLE)

3.2 Renal Manifestations

Renal involvement typically manifests as rapidly progressive glomerulonephritis (RPGN) with:

• Hematuria (microscopic or macroscopic)
• Proteinuria (typically non-nephrotic)
• Progressive decline in renal function
• Hypertension
• Oliguria or anuria in severe cases

3.3 Systemic Manifestations

Systemic features vary by condition:

• GPA: Upper respiratory tract involvement (sinusitis, otitis, saddle nose deformity), ocular inflammation, cutaneous vasculitis
• MPA: Constitutional symptoms, mononeuritis multiplex, cutaneous vasculitis
• EGPA: Asthma, peripheral eosinophilia, mononeuritis multiplex, cardiac involvement
• SLE: Malar rash, photosensitivity, oral ulcers, arthritis, serositis, neurologic manifestations

4. Diagnostic Approach

A systematic diagnostic approach is essential for timely identification and management of renopulmonary syndromes.

4.1 Clinical Evaluation

1. Comprehensive history focusing on:

   • Respiratory symptoms (hemoptysis, dyspnea)
   • Urinary symptoms
   • Constitutional symptoms
   • Extra-pulmonary and extra-renal manifestations
   • Medication history
   • Environmental exposures

2. Physical examination with attention to:

   • Vital signs, including blood pressure
   • Respiratory system evaluation
   • Signs of vasculitis (purpura, nodules)
   • Signs of systemic disease (rash, arthritis)

4.2 Laboratory Investigations

4.2.1 Initial Screening Tests

• Complete blood count with differential
• Comprehensive metabolic panel
• Urinalysis and urine microscopy
• 24-hour urine protein or protein-to-creatinine ratio
• Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)

4.2.2 Specific Immunological Tests

• Anti-neutrophil cytoplasmic antibodies (ANCA)

  • Immunofluorescence pattern: cytoplasmic (c-ANCA) or perinuclear (p-ANCA)
  • Enzyme-linked immunosorbent assay (ELISA) for PR3-ANCA and MPO-ANCA

• Anti-glomerular basement membrane (anti-GBM) antibodies

• Antinuclear antibodies (ANA) and specific antibodies:

  • Anti-double-stranded DNA (anti-dsDNA)
  • Anti-Smith (anti-Sm)
  • Anti-Ro/SSA and anti-La/SSB

• Complement levels (C3, C4, CH50)

• Cryoglobulins and rheumatoid factor

4.2.3 Other Laboratory Tests

• Arterial blood gas analysis
• Lactate dehydrogenase (LDH)
• Coagulation profile
• Blood cultures (to exclude infectious etiologies)

4.3 Bronchoscopy and Bronchoalveolar Lavage (BAL)

Bronchoscopy with BAL is crucial for evaluating pulmonary hemorrhage:

• Progressively bloodier return in sequential aliquots suggests alveolar hemorrhage
• Hemosiderin-laden macrophages on cytological examination
• Cultures to exclude infection
• Cell count and differential
• Cytological examination for malignant cells

4.4 Renal Biopsy

Renal biopsy remains the gold standard for diagnosing and classifying glomerulonephritis:

• Light microscopy: pattern of glomerular injury (crescentic, proliferative, etc.)
• Immunofluorescence: pattern of immune deposits
  • Linear IgG deposits (anti-GBM disease)
  • Granular immune complex deposits (lupus nephritis)
  • Pauci-immune pattern (ANCA-associated vasculitis)
• Electron microscopy: ultrastructural changes and location of deposits

4.5 Pulmonary Biopsy

Lung biopsy may be considered when:

• Diagnosis remains unclear after non-invasive testing
• Atypical presentations
• Suspicion of alternative diagnoses (infection, malignancy)

Techniques include:

• Transbronchial biopsy (less invasive but lower yield)
• Video-assisted thoracoscopic surgery (VATS) or open lung biopsy (higher yield)

5. Radiological Evaluation

Imaging plays a crucial role in the diagnosis and monitoring of renopulmonary syndromes.

5.1 Chest Radiography

Chest radiography findings include:

• Bilateral, diffuse alveolar opacities (typical of diffuse alveolar hemorrhage)
• Nodules with or without cavitation (GPA)
• Interstitial patterns (SLE, MPA)
• Pleural effusions (more common in SLE)

5.2 High-Resolution Computed Tomography (HRCT)

HRCT provides detailed assessment of pulmonary involvement:

• Diffuse Alveolar Hemorrhage:

  • Ground-glass opacities
  • Consolidations
  • Smooth interlobular septal thickening (crazy paving pattern)
  • Sparing of peripheral lung regions in some cases

• GPA:

  • Multiple nodules (0.5-10 cm) with or without cavitation
  • Ground-glass opacities
  • Tracheobronchial abnormalities
  • Pleural and pericardial effusions (less common)

• MPA:

  • Ground-glass opacities
  • Consolidations
  • Interlobular septal thickening
  • Rarely nodules or cavities

• EGPA:

  • Transient, patchy, peripheral consolidations
  • Ground-glass opacities
  • Centrilobular nodules
  • Bronchial wall thickening

• SLE:

  • Ground-glass opacities
  • Interstitial lung disease patterns
  • Pleural effusions
  • Acute lupus pneumonitis (consolidation)

5.3 Renal Imaging

Renal ultrasonography typically shows:

• Normal or enlarged kidneys in acute presentations
• Preserved corticomedullary differentiation
• Increased echogenicity in advanced disease

CT or MRI may demonstrate:

• Renal size and morphology
• Perfusion abnormalities
• Exclusion of obstructive uropathy or other structural abnormalities

5.4 Other Relevant Imaging

• Sinus CT (for upper respiratory tract involvement in GPA)
• Echocardiography (for cardiac involvement, especially in EGPA)
• Vascular imaging (for assessment of medium-vessel vasculitis)

6. Management Approaches

The management of renopulmonary syndromes requires a multidisciplinary approach, often in intensive care settings for severe presentations.

6.1 General Principles

1. Rapid assessment and stabilization:

   • Airway management
   • Oxygen supplementation or mechanical ventilation as needed
   • Hemodynamic support
   • Correction of electrolyte and acid-base disturbances

2. Disease activity assessment:

   • Clinical evaluation
   • Laboratory parameters
   • Imaging findings
   • Organ function assessment

3. Multidisciplinary collaboration between:

   • Critical care specialists
   • Nephrologists
   • Pulmonologists
   • Rheumatologists
   • Pathologists
   • Radiologists

6.2 Specific Therapeutic Approaches

6.2.1 Induction Therapy

Corticosteroids:

• High-dose intravenous methylprednisolone (500-1000 mg daily for 3 days)
• Followed by oral prednisone (1 mg/kg/day, typically not exceeding 60-80 mg daily)
• Gradual tapering based on clinical response

Cyclophosphamide:

• Intravenous regimen: 15 mg/kg every 2-3 weeks (dose adjustments for renal function and age)
• Oral regimen: 2 mg/kg/day (adjusted for renal function and age)
• Duration typically 3-6 months

Rituximab:

• 375 mg/m² weekly for 4 weeks or
• 1000 mg on days 0 and 14
• Particularly effective in ANCA-associated vasculitis
• Preferred in patients of childbearing age or with high cumulative cyclophosphamide exposure

6.2.2 Plasma Exchange (PLEX)

Indications:

• Anti-GBM disease with pulmonary hemorrhage or severe renal involvement
• ANCA-associated vasculitis with:
  • Severe renal involvement (creatinine >5.7 mg/dL or requiring dialysis)
  • Diffuse alveolar hemorrhage

Protocol:

• 7-10 treatments over 14 days
• 60 mL/kg volume exchange
• Replacement with albumin or fresh frozen plasma

6.2.3 Maintenance Therapy

After achieving remission (typically 3-6 months):

Azathioprine:

• 2 mg/kg/day (maximum 200 mg/day)
• Duration: 18-24 months

Mycophenolate mofetil:

• 2-3 g/day in divided doses
• Alternative to azathioprine, particularly in lupus nephritis

Rituximab:

• 500-1000 mg every 6 months
• Emerging evidence supports its role in maintenance therapy

Methotrexate:

• 20-25 mg weekly (with folic acid supplementation)
• Alternative in patients with preserved renal function

6.2.4 Management of Specific Conditions

Anti-GBM Disease:

• Triple therapy with corticosteroids, cyclophosphamide, and plasma exchange
• Aggressive early intervention is crucial, especially with pulmonary hemorrhage
• Duration of immunosuppression typically shorter (6 months) due to lower relapse rates

ANCA-Associated Vasculitis:

• Corticosteroids with either cyclophosphamide or rituximab for induction
• Azathioprine, mycophenolate mofetil, or rituximab for maintenance
• Plasma exchange for severe manifestations
• Maintenance therapy for 18-24 months with monitoring of ANCA titers

Lupus Nephritis with Pulmonary Involvement:

• Class-dependent approach to treatment
• Corticosteroids with mycophenolate mofetil or cyclophosphamide for induction
• Mycophenolate mofetil or azathioprine for maintenance
• Consideration of belimumab for refractory cases

6.3 Supportive Care

6.3.1 Respiratory Support

• Oxygen supplementation
• Non-invasive ventilation when appropriate
• Lung-protective ventilation strategies for intubated patients
  • Low tidal volumes (6 mL/kg predicted body weight)
  • Appropriate PEEP titration
  • Prone positioning in severe cases
• Extracorporeal membrane oxygenation (ECMO) in refractory cases

6.3.2 Renal Support

• Meticulous fluid and electrolyte management
• Renal replacement therapy (RRT) when indicated:
  • Severe acidosis
  • Hyperkalemia
  • Fluid overload unresponsive to diuretics
  • Uremic symptoms
• Continuous renal replacement therapy (CRRT) for hemodynamically unstable patients

6.3.3 Prophylactic Measures

• Pneumocystis jirovecii pneumonia prophylaxis:

  • Trimethoprim-sulfamethoxazole (first-line)
  • Alternatives: dapsone, atovaquone, or pentamidine

• Gastric protection:

  • Proton pump inhibitors during high-dose corticosteroid therapy

• Bone health:

  • Calcium and vitamin D supplementation
  • Consideration of bisphosphonates for prolonged corticosteroid use

• Cardiovascular risk reduction:

  • Blood pressure control
  • Lipid management
  • Lifestyle modifications

6.4 Monitoring and Follow-up

6.4.1 Clinical Monitoring

• Regular assessment of respiratory symptoms
• Monitoring of renal function and urinalysis
• Evaluation of extra-pulmonary and extra-renal manifestations
• Assessment for treatment-related adverse effects

6.4.2 Laboratory Monitoring

• Complete blood count
• Renal function tests
• Urinalysis and urine protein quantification
• Inflammatory markers (ESR, CRP)
• Autoantibody titers (ANCA, anti-GBM, others as relevant)
• Drug-specific monitoring (e.g., cyclophosphamide metabolites)

6.4.3 Imaging Follow-up

• Chest radiography or HRCT based on clinical indication
• Renal ultrasonography as needed

7. Prognosis and Outcomes

Prognosis varies considerably depending on the underlying condition and severity at presentation:

7.1 Anti-GBM Disease

• Poor renal prognosis if creatinine >5.7 mg/dL or requiring dialysis at presentation
• Better pulmonary outcomes with prompt treatment
• Relapse rates generally low (5-10%)
• Early treatment is crucial for organ preservation

7.2 ANCA-Associated Vasculitis

• Five-year survival rates approximately 75-80%
• Relapse rates 30-50% over 5 years
• Better outcomes with:
  • Preserved renal function at diagnosis
  • Prompt initiation of treatment
  • Absence of severe pulmonary hemorrhage

7.3 Lupus Nephritis with Pulmonary Involvement

• Variable outcomes depending on nephritis class and severity of pulmonary disease
• Five-year renal survival approximately 80-90%
• Higher relapse rates compared to other renopulmonary syndromes

7.4 Predictors of Poor Outcomes

• Delayed diagnosis
• Severe renal impairment at presentation
• Requirement for mechanical ventilation
• Advanced age
• Multiple comorbidities
• Treatment-related complications

8. Emerging Therapies and Future Directions

Recent advances and ongoing research in renopulmonary syndromes include:

8.1 Biological Agents

• C5a Receptor Inhibitors (Avacopan):

  • Complement pathway inhibition
  • Potential steroid-sparing effects in ANCA-associated vasculitis

• B-cell Targeted Therapies:

  • Obinutuzumab (type II anti-CD20 antibody)
  • Belimumab (anti-BLyS/BAFF) in lupus nephritis

• Targeted Plasma Cell Therapies:

  • Bortezomib and other proteasome inhibitors
  • Potential in refractory disease

8.2 Biomarker Development

• Urinary biomarkers for early detection of renal involvement
• Serum biomarkers for disease activity assessment
• Predictive biomarkers for treatment response and relapse

8.3 Novel Therapeutic Approaches

• Complement inhibition strategies
• JAK inhibitors
• IL-6 pathway blockade
• Antifibrotic agents for chronic lung and kidney disease

9. Conclusion

Renopulmonary syndromes present significant diagnostic and therapeutic challenges in critical care medicine. A systematic approach to diagnosis, incorporating clinical, laboratory, radiological, and histopathological data, is essential for timely intervention. Management requires a multidisciplinary approach, with immunosuppressive therapy tailored to the underlying condition and disease severity. Despite advances in therapy, these conditions continue to be associated with significant morbidity and mortality, highlighting the need for ongoing research into novel therapeutic targets and approaches.

References

1. Segelmark M, Wieslander J. The molecular basis of Goodpasture's disease. Nephrol Dial Transplant. 2022;37(1):55-61. doi:10.1093/ndt/gfab165

2. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232. doi:10.1056/NEJMoa0909905

3. Jones RB, Furuta S, Tervaert JW, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. 2015;74(6):1178-1182. doi:10.1136/annrheumdis-2014-206404

4. Jayne DRW, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180-2188. doi:10.1681/ASN.2007010090

5. Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622-631. doi:10.1056/NEJMoa1803537

6. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771-1780. doi:10.1056/NEJMoa1404231

7. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36-44. doi:10.1056/NEJMoa020286

8. Furuya Y, Satoh T, Kuwana M. Interestitial lung disease in systemic vasculitides. Clin Med Insights Circ Respir Pulm Med. 2019;13:1179548419841295. doi:10.1177/1179548419841295

9. Flores-Suárez LF, Alba MA, Mateos-Toledo H, Ruiz N. Pulmonary involvement in systemic vasculitis. Curr Rheumatol Rep. 2017;19(9):56. doi:10.1007/s11926-017-0683-3

10. McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2017;12(7):1162-1172. doi:10.2215/CJN.01380217

11. Göçeroğlu A, Berden AE, Fiocco M, et al. ANCA-associated glomerulonephritis: risk factors for renal relapse. PLoS One. 2016;11(12):e0165402. doi:10.1371/journal.pone.0165402

12. Schwarz MI, Brown KK. Small vessel vasculitis of the lung. Thorax. 2000;55(6):502-510. doi:10.1136/thorax.55.6.502

13. Geri G, Terrier B, Heshmati F, et al. Effect of plasma exchange in acute respiratory failure due to anti-neutrophil cytoplasmic antibody-associated vasculitis. Crit Care. 2018;22(1):328. doi:10.1186/s13054-018-2264-x

14. De Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670-680. doi:10.7326/0003-4819-150-10-200905190-00004

15. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi:10.1136/annrheumdis-2019-215089

16. Sinico RA, Di Toma L, Radice A. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev. 2013;12(4):477-482. doi:10.1016/j.autrev.2012.08.006

17. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasmic antibody-associated vasculitis. Ann Rheum Dis. 2007;66(5):605-617. doi:10.1136/ard.2006.062711

18. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi:10.1002/art.37715

19. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-1594. doi:10.1136/annrheumdis-2016-209133

20. Canney M, O'Hara PV, McEvoy CM, et al. Spatial and temporal clustering of anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2016;11(8):1392-1399. doi:10.2215/CJN.13591215

21. Tesar V, Hruskova Z. Avacopan in the treatment of ANCA-associated vasculitis. Expert Opin Investig Drugs. 2018;27(5):491-496. doi:10.1080/13543784.2018.1472234

22. Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756-2767. doi:10.1681/ASN.2016111179

23. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134(11):1033-1042. doi:10.7326/0003-4819-134-11-200106050-00009

24. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417-427. doi:10.1056/NEJMoa1213277

25. Huart A, Josse AG, Chauveau D, et al. Outcomes of patients with Goodpasture syndrome: A nationwide cohort-based study from the French Society of Hemapheresis. J Autoimmun. 2016;73:24-29. doi:10.1016/j.jaut.2016.05.015

26. Cordier JF, Cottin V. Alveolar hemorrhage in vasculitis: primary and secondary. Semin Respir Crit Care Med. 2011;32(3):310-321. doi:10.1055/s-0031-1279827

27. Gaffo AL. Diagnostic approach to ANCA-associated vasculitides. Rheum Dis Clin North Am. 2010;36(3):491-506. doi:10.1016/j.rdc.2010.05.009

28. Quartuccio L, Bond M, Isola M, et al. Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors. J Autoimmun. 2020;108:102397. doi:10.1016/j.jaut.2019.102397

29. West S, Arulkumaran N, Ind PW, Pusey CD. Diffuse alveolar haemorrhage in ANCA-associated vasculitis. Intern Med. 2013;52(1):5-13. doi:10.2169/internalmedicine.52.8863

30. Hruskova Z, Stel VS, Jayne D, et al. Characteristics and outcomes of patients with systemic vasculitis admitted to intensive care units: a retrospective study. Rheumatology (Oxford). 2020;59(10):3081-3089. doi:10.1093/rheumatology/keaa067